2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
4
Carcinoma, Renal Cell
4
Sarcoma
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Castration-resistant Prostate Cancer
2
Urologic Neoplasms
1
Stomach Neoplasms
1
Osteosarcoma
1
Melanoma
1
Lymphatic Metastasis
1
Ependymoma
1
Colonic Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Breast Neoplasms
1
Bone Neoplasms
1
Adenocarcinoma
1
Abdominal Neoplasms
1
Interventions
pembrolizumab
156
Gemcitabine
140
Capecitabine
123
Paclitaxel
120
Fluorouracil
117
Oxaliplatin
110
Bevacizumab
106
Nivolumab
99
Leucovorin
97
Docetaxel
97
Cisplatin
89
Radiosurgery
88
Irinotecan
87
Carboplatin
85
Cetuximab
72
Cyclophosphamide
71
Magnetic Resonance Spectroscopy
68
Specimen Handling
60
Radiotherapy
60
Trastuzumab
59
Biopsy
59
Ipilimumab
53
Drug Therapy
51
Everolimus
48
Pemetrexed
46
Albumin-Bound Paclitaxel
45
130-nm albumin-bound paclitaxel
44
Doxorubicin
42
Fulvestrant
40
aldesleukin
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Metastasectomy
×
Clear all
NCT05352178
2024-07-03
SPARKLE
Universitaire Ziekenhuizen KU Leuven
Phase 3
Recruiting
873 enrolled
NCT06121700
2023-11-08
Miracle-G
Fudan University
Phase 2
Recruiting
55 enrolled